Healing & Recovery Peptide

TB-500: Thymosin Beta-4 Synthetic Fragment

A UK-focused, evidence-based comparison of TB-500 and Dihexa — mechanism, benefits, dosing, side effects, legal status, and stacking.

TB-500 is a synthetic short-form peptide named after the active region of the endogenous protein thymosin beta-4, a 43-amino-acid actin-binding protein involved in cell migration, wound healing, angiogenesis, and tissue regeneration. The research-chemical TB-500 sold commercially is typically a much shorter acetylated synthetic peptide (around 7 amino acids) corresponding to the active fragment of thymosin beta-4 rather than the full-length protein. The full-length recombinant thymosin beta-4 has been investigated under the developmental name RGN-259 by RegeneRx Biopharmaceuticals for dry eye disease, neurotrophic keratitis, and dermal wound healing, though commercial approval has not been achieved in major markets.

What is TB-500?

The pharmaceutical-grade thymosin beta-4 is a 43-amino-acid protein. The "TB-500" sold in the research-chemical market is typically a synthetic acetylated heptapeptide corresponding to the LKKTETQ actin-binding domain of thymosin beta-4. This is an important practical distinction — buyers should be aware that "TB-500" rarely refers to full-length thymosin beta-4 and instead refers to a synthetic short-form. The compound is sold as lyophilised powder for reconstitution into subcutaneous or intramuscular injection solution. Several hundred published papers exist on thymosin beta-4 and its fragments, including a small clinical trial literature in dry eye and dermal wound healing.

Chemistry: Acetyl-LKKTETQ · synthetic fragment of thymosin beta-4 · MW 889.04 g/mol
Origin: Originally derived from thymosin beta-4 (RegeneRx Biopharmaceuticals); the synthetic short-form research-chemical version diverged 2000s
Primary route: Subcutaneous or intramuscular injection
Pharmacokinetics: Days-long systemic effects from a single dose due to actin-binding and angiogenic cascade. Typical injection frequency 2-3 times per week.
Class: Synthetic thymosin beta-4 fragment

Mechanism of Action

Thymosin beta-4 binds G-actin and regulates the actin cytoskeleton, enabling cell migration during tissue repair. Downstream effects relevant to therapeutic use include: promotion of cell migration in wound healing (keratinocytes, endothelial cells, fibroblasts); angiogenesis promotion via VEGF and bFGF pathways; upregulation of laminin-5 for basement membrane integrity in skin and corneal repair; reduction of inflammation via NF-κB modulation; and activation of stem cell migration from bone marrow to sites of injury. In cardiac models thymosin beta-4 promotes epicardial cell migration and reduces post-infarct scarring. In CNS models the effect is less well characterised, with some preclinical signal for neurite outgrowth and oligodendrocyte support, but human CNS data is essentially absent. The short-form TB-500 fragment retains the actin-binding and angiogenic activity of the parent protein but may have a narrower overall profile.

Proposed Benefits

Most reported and most evidence-supported benefits are soft tissue healing (tendon, ligament, muscle), accelerated wound healing, angiogenesis in ischaemic tissue, and reduced post-injury scar formation. In nootropic-adjacent use, reported effects include faster recovery from intense training, reduced post-exercise soreness, better sleep quality, and a generalised systemic "well-being" feeling over multi-week courses. The compound is not a classical cognitive enhancer — it does not produce acute focus, stamina, or mood effects. Its inclusion in nootropic stacks is typically as a recovery and angiogenesis partner rather than as a primary cognitive agent. Some users report cognitive benefit secondary to better sleep and reduced systemic inflammation; this is plausible but not formally demonstrated.

Evidence Base

The thymosin beta-4 literature is substantial (~500+ papers) but the TB-500 short-form synthetic specifically has thinner evidence than the parent protein. Key references: Goldstein et al. 2005 (Nature Cell Biology review of thymosin beta-4 in tissue repair); Sosne et al. 2007-2015 series on corneal wound healing; Bock-Marquette et al. 2004 (Nature, cardiac repair); Smart et al. 2007 (Nature, cardiac progenitor cell activation). Clinical trial data exists for the full-length recombinant protein (RGN-259) in dry eye disease and neurotrophic keratitis, with positive Phase 2-3 results but no marketing approval in major Western markets. The research-chemical short-form TB-500 has minimal independent human evidence; almost all human use is community self-experimentation.

Dosage & Administration

No medically approved dose exists. Community-reported protocols typically use 2-5 mg subcutaneously twice per week for 4-8 weeks as a healing course, followed by a maintenance phase of 2 mg once every 1-2 weeks. The high per-dose milligram amount (much higher than peptides like Semax or Dihexa) reflects TB-500's actin-binding mode of action requiring substantial molecular occupancy. Subcutaneous administration near a specific injury site is sometimes used. Reconstitute lyophilised powder with bacteriostatic water and refrigerate; use within 14-21 days. Oral and intranasal routes are not viable — the compound is not orally bioavailable and is too large for cribriform plate transport.

This is a community-reported protocol summary, not a medical recommendation. There is no established human dose. Consult a qualified healthcare professional before using any research compound.

Side Effects & Risks

Reported acute side effects are minimal: injection site reactions, occasional brief lethargy or "flu-like" feeling in the first 24 hours after a dose (sometimes attributed to immune modulation), very rare allergic reactions. Theoretical concerns are the same as for any pro-angiogenic peptide: potential acceleration of tumour vascularisation, and unknown long-term effects of sustained actin cytoskeleton modulation. Contraindications: active or recent cancer (the strongest contraindication for any pro-angiogenic compound), pregnancy/breastfeeding (no data), known hypersensitivity, active autoimmune disease (theoretical concern from immune modulation). No documented drug interactions, but caution with anticoagulants and immunosuppressants given the angiogenic and immune-modulating profile.

UK Legal Status

UK: not a controlled substance, not licensed by MHRA, not scheduled under the Psychoactive Substances Act. Legal as a research chemical for laboratory use. WADA: TB-500 is on the WADA Prohibited List as a peptide hormone / growth factor; athletes subject to anti-doping testing should not use it. US: FDA does not approve the compound for human use; commercial sale for human consumption is unlawful. Personal-use import of small quantities of research-chemical material exists in a grey area common to most research peptides.

TB-500 vs Dihexa

TB-500 and Dihexa share an angiogenesis component (both promote new blood vessel formation through different upstream signals) but otherwise serve distinct purposes. TB-500 is a systemic healing and tissue regeneration peptide focused on soft tissue, wound healing, and cardiovascular repair contexts. Dihexa is a CNS-targeted synaptogenic peptide driving cognitive plasticity via HGF/c-Met. The two compounds occupy non-overlapping therapeutic niches and could in principle stack without competition. For users where the goal is cognitive enhancement, TB-500 offers little direct benefit; for users where the goal is injury recovery, TB-500 is a more direct tool than Dihexa.

Stacking with Dihexa

TB-500 is most commonly stacked with BPC-157 — the canonical "healing twin stack" used in injury rehabilitation, where BPC-157 covers connective tissue and gut-brain effects and TB-500 covers actin-mediated cell migration and angiogenesis. With Dihexa the rationale would be a comprehensive plasticity / regeneration protocol covering CNS synaptogenesis (Dihexa) and systemic angiogenesis / tissue repair (TB-500). No published interaction data exists. Avoid stacking with active cancer treatment, pregnancy, or in users with uncharacterised lumps or undiagnosed dermatological lesions. Always allow a clean diagnostic baseline before starting a long TB-500 course.

Frequently Asked Questions

Not exactly. Thymosin beta-4 is the full-length 43-amino-acid endogenous protein. TB-500 sold in the research-chemical market is typically a synthetic short-form (around 7 amino acids) corresponding to the active fragment of thymosin beta-4.

Yes. TB-500 is on the WADA Prohibited List as a peptide hormone / growth factor. Athletes subject to anti-doping testing should not use it.

No. TB-500 is not orally bioavailable. Subcutaneous or intramuscular injection is required.

Typical community protocols use 2-5 mg twice per week. The long functional duration (days) means daily injection is unnecessary.

There is no clinical evidence that TB-500 causes cancer. The theoretical concern is that pro-angiogenic compounds could accelerate growth of existing vascularised tumours. Anyone with active malignancy should not use TB-500.

TB-4-Frag is another name for the short-form synthetic fragment that is typically sold as TB-500. Full-length recombinant thymosin beta-4 is sold under the developmental name RGN-259 or as Tβ4.

The Bottom Line

TB-500 is a recovery-focused peptide centred on actin cytoskeleton modulation, angiogenesis, and soft tissue healing. It is not a cognitive enhancer in the sense Dihexa, Semax, or Selank are. Its place in a Dihexa-adjacent protocol is as a complementary systemic regeneration tool, particularly for users with concurrent injury or recovery needs. WADA-prohibited and cancer-contraindicated; otherwise a reasonable peptide for users with specific recovery goals.